Prime Therapeutics, a pharmacy benefit manager which serves nearly 33 million people and is collectively owned by 19 Blue Cross and Blue Shield plans or affiliates, has followed action by fellow PBM Express Scripts and announced it will put Viatris/Biocon’s interchangeable insulin glargine products on its preferred national formulary.
Viatris Scoops Another Preferred Formulary Listing For Interchangeable Semglee
Prime Therapeutics Decision For Insulin Glargine Biosimilar Follows Express Scripts
Prime Therapeutics, the large PBM serving tens of millions of members, insisted it was “not beholden to rebates” as it joined Express Scripts in announcing plans to move Viatris/Biocon’s interchangeable biosimilar insulin glargine products to its preferred national formulary.
More from Biosimilars
More from Products
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.